ADXS - Advaxis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.2382
-0.1388 (-36.82%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.3770
Open0.2835
Bid0.2300 x 1000
Ask0.2460 x 1100
Day's Range0.2220 - 0.2835
52 Week Range0.2220 - 3.5800
Volume3,957,791
Avg. Volume634,457
Market Cap16.554M
Beta (3Y Monthly)4.69
PE Ratio (TTM)N/A
EPS (TTM)-1.5380
Earnings DateDec 18, 2018 - Dec 24, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.33
Trade prices are not sourced from all markets
  • Zacks4 days ago

    Will Advaxis (ADXS) Report Negative Earnings Next Week? What You Should Know

    Advaxis (ADXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Simply Wall St.4 days ago

    Could Advaxis, Inc.’s (NASDAQ:ADXS) Investor Composition Influence The Stock Price?

    The big shareholder groups in Advaxis, Inc. (NASDAQ:ADXS) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions Read More...

  • Business Wire18 days ago

    Advaxis to Present at LD Micro Main Event

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

  • Business Wirelast month

    Advaxis to Present Poster Entitled “Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy” at Society for Immunotherapy of Cancer Annual Meeting

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC). The poster, entitled “Natural killer (NK) cells orchestrate the antitumor activities of Listeria monocytogenes (Lm)-based immunotherapy,” evaluated the impact of Lm-based immunotherapy on the activation of NK cells in a murine model of human papillomavirus (HPV)-associated tumors.

  • Business Wirelast month

    Advaxis Provides Update on Clinical Pipeline

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it will be continuing its ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV). The current trial design has a planned sample size of 450 subjects to maintain adequate statistical power over a broader range of survival outcomes, as well as a pre-planned interim analysis (IA) of safety and efficacy. The Company anticipates that over the next couple of months it will finalize the redesign of the trial and review it with the U.S. Food and Drug Administration (FDA).

  • Business Wire2 months ago

    Advaxis to Host Business Update Conference Call on November 2, 2018

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018.

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire3 months ago

    Advaxis to Present at the Cantor Fitzgerald Global Healthcare Conference

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Genomic ...

  • Advaxis Inc (NASDAQ:ADXS): How Much Growth Is Left In Healthcare?
    Simply Wall St.3 months ago

    Advaxis Inc (NASDAQ:ADXS): How Much Growth Is Left In Healthcare?

    Advaxis Inc (NASDAQ:ADXS), a US$53.9m small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence of chronicRead More...

  • Business Wire3 months ago

    Advaxis Announces Closing of Its Public Offering of Common Stock and Warrants

     Advaxis, Inc. (ADXS) (“Advaxis” or the “Company”) announced today the closing of its previously announced underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock. Each share of common stock was sold together in a fixed combination with a warrant to purchase 0.85 shares of common stock at a combined offering price of $1.20 per share and related warrant. The gross proceeds of the offering were approximately $20 million, before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Stocks that hit 52-week highs Sept. 7.) Amgen, Inc. (NASDAQ: AMGN )/p BioSpecifics Technologies ...

  • Associated Press3 months ago

    Advaxis: Fiscal 3Q Earnings Snapshot

    On a per-share basis, the Princeton, New Jersey-based company said it had a loss of 27 cents. The biotechnology company posted revenue of $1.1 million in the period. In the final minutes of trading on ...

  • Business Wire3 months ago

    Advaxis Reports Fiscal 2018 Third Quarter Business Highlights and Financial Results

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced business highlights and financial results for the fiscal year 2018 third quarter, ended July 31, 2018.

  • Business Wire3 months ago

    Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants

    Advaxis, Inc. (ADXS) (“Advaxis” or the “Company”) announced today the pricing of an underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock. Each share of common stock is being sold together in a fixed combination with a warrant to purchase 0.85 shares of common stock. The gross proceeds of the offering to the Company are expected to be approximately $20 million, before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Sept. 6) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR )(announced positive ...

  • Business Wire3 months ago

    Advaxis, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants

    Advaxis, Inc. (ADXS) (“Advaxis” or the “Company”) announced today that it intends to offer and sell in an underwritten public offering shares of its common stock, with each share of common stock to be sold together in a fixed combination with a warrant to purchase common stock. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering.

  • Business Wire3 months ago

    Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, and OS Therapies LLC, a clinical-stage therapeutic company focused on the identification, development and commercialization of treatments for osteosarcoma, today announced that Advaxis has granted a license to OS Therapies for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans.

  • Business Wire5 months ago

    Advaxis Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA) has allowed the Company’s IND application for its ADXS-HOT drug candidate for non-small cell lung cancer (NSCLC). Advaxis anticipates that because of this timely allowance, the first patient in the Phase 1/2 trial for this NSCLC drug candidate will be dosed by the end of 2018.

  • ACCESSWIRE5 months ago

    Free Technical Research on Advaxis and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on ADXS sign up now at www.wallstequities.com/registration. On Wednesday, July 25, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories.

  • Why Investors Are Excited about Advaxis
    Market Realist5 months ago

    Why Investors Are Excited about Advaxis

    Advaxis (ADXS), in collaboration with Merck & Co. (MRK), is conducting a Phase 1 Part 2 trial to evaluate the safety and efficacy of ADXS-PSA as a monotherapy and in combination with Merck’s Keytruda in patients with previously treated metastatic, castration-resistant prostate cancer. In the trial, 13 patients were evaluated on monotherapy and 37 patients were evaluated on combination therapy. The safety profile was found to be consistent with prior clinical studies that used Lm Technology.

  • FDA Lifts Hold on Clinical Trial: Major Boost for Advaxis
    Market Realist5 months ago

    FDA Lifts Hold on Clinical Trial: Major Boost for Advaxis

    Advaxis (ADXS) is conducting a Phase 1 Part 2 open-label multicenter study for evaluating the safety and efficacy of axalimogene filolisbac in combination with durvalumab. Durvalumab is MedImmune’s investigational anti-PD-L1 checkpoint inhibitor for patients with metastatic squamous or non-squamous carcinoma of the cervix and metastatic HPV-related squamous cell carcinoma of the head and neck. On March 9, the study was placed on clinical hold by the FDA after its review of a safety report showed a grade-five serious adverse event occurring in February.

  • Advaxis’s Research and Development Strategy
    Market Realist5 months ago

    Advaxis’s Research and Development Strategy

    Advaxis (ADXS) has a license from the University of Pennsylvania for exclusive access to the proprietary formulation of attenuated Lm Technology. Across multiple clinical trials and in various tumor types, more than 530 patients have been dosed with Advaxis’s Lm (listeria monocytogenes) Technology. The company believes that its Lm Technology immunotherapies can complement and address unmet needs in the current oncology treatment landscape.

  • Analyzing Advaxis’s Financial Performance
    Market Realist5 months ago

    Analyzing Advaxis’s Financial Performance

    In Q2 2018, Advaxis (ADXS) generated revenues of $1.75 million compared to $3.43 million in Q1 2017. The decrease was due to a change in the estimated performance period for upfront fees received by Advaxis from Amgen (AMGN) for the collaboration agreement they signed in August 2016. For fiscal 2018 and 2019, the company is expected to generate revenues of $7.59 million and $7.68 million, respectively.